Clinical trials: Hematologic
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Study CC-90002-AML-001 is an open-label, Phase 1 dose escalation (Part A) and expansion (Part B), clinical study of CC-90002, administered by intravenous (IV) infusion, in subjects with relapsed and/or primary refractory AML and…
- Trial name
- NCT02641002
- Testing
- CC-90002
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Celgene
Leukemia, Lymphocytic, Acute
T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis
To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).
- Trial name
- NCT01078337
- Testing
- bone marrow aspiration, peripheral blood sampling
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases.
- Conditions
- Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
- Trial name
- NCT00351975
- Testing
- Belinostat, Azacitidine, Laboratory Biomarker Analysis
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Malignant, Non-hodgkin Lymphoma
DS-3201b in Participants With Lymphomas
DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to…
- Trial name
- NCT02732275
- Testing
- DS-3201b
- Where
- 20 sites in United States, Japan
- Volunteers
- 100 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Multiple Myeloma
Expanded Access Treatment Protocol CA204-143
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S.
- Trial name
- NCT02368301
- Testing
- Elotuzumab in combination with Lenalidomide and Dexamethasone
- Sponsor
- Bristol-Myers Squibb
Leukemia
Sleep, Fatigue, and Dexamethosone in Children With Leukemia
The purpose of this study is to determine the relationship between dexamethosone (steroid) and children's sleep and fatigue.
- Trial name
- NCT00075101
- Testing
- Dexamethosone
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- National Institute of Nursing Research (NINR)
Colorectal Cancer, Colorectal Carcinoma
Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases
Colorectal cancer (CRC) is the third most common malignancy worldwide and is often metastatic at diagnosis. Despite progresses in surgical techniques and the introduction of novel chemotherapy regimens, many patients still suffer…
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Stage IV Colon Cancer
- Trial name
- PLTCRC (NCT03717519)
- Testing
- Measurement of platelet count at diagnosis
- Where
- Italy
- Volunteers
- 196 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
This phase II trial studies the immune response after stem cell transplant in human immunodeficiency virus (HIV)-positive patients with hematologic cancer (blood cancer).
- Trial name
- NCT00968630
- Testing
- Laboratory Biomarker Analysis, Leukapheresis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
CD7 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma. Approximately 10-30% of cute myeloid leukemia(AML) patients exhibit CD7 expression, particularly in early myeloid progenitor cell-derived…
- Trial name
- NCT07120607
- Testing
- CD7 CAR-γδT cell（QH106）, Fludarabine (FLU), Cyclophosphamide (CTX)
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Acute Lymphoblastic Leukemia
Effects of Home-Based Exercise Program in Children After Acute Lymphoblastic Leukemia
This prospective randomized controlled study aimed to investigate the effects of a home-based exercise program on physical functions, inflammatory markers, and Brain-Derived Neurotrophic Factor (BDNF) in children followed after…
- Trial name
- NCT06664736
- Testing
- Exercise, Physical activity
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Gazi University
Bloodstream Infection, Gram Negative Infections
Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia Patients
The goal of this clinical trial is to learn if a personalized duration of antibiotic therapy, based on clinical stability, is as effective as a standard duration of at least 10 days in hospitalized patients with hematologic…
- Conditions
- Bloodstream Infection, Gram Negative Infections, Bacteraemia Caused by Gram-Negative Bacteria, Febrile Neutropenia (FN)
- Trial name
- PERaSTrA (NCT07372131)
- Testing
- Clinical Stability-Driven Antibiotic Discontinuation Strategy, Standard of Care Antibiotic Duration
- Where
- Italy
- Volunteers
- 172 people
- Sponsor
- Valeria Cento
Chronic Lymphatic Leukemia
Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment
Despite certain notable progress, treatment of patients with Chronic Lymphatic Leukemia (CLL) is still disappointing. Although thanks to the use of treatment of (immune) chemotherapy, mainly based on fludarabine, rituximab and…
- Trial name
- LENDEX-LLC-09 (NCT01246557)
- Testing
- Lenalidomide, Dexamethasone
- Where
- 6 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Multiple Myeloma
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
This is an open label Phase II study to determine the rate of improvement in response of patients with previously treated multiple myeloma to imetelstat alone or in combination with lenalidomide maintenance therapy.
- Trial name
- NCT01242930
- Testing
- Imetelstat (7.5 mg/kg), lenalidomide standard of care, Imetelstat (9.4 mg/kg)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Geron Corporation
Multiple Myeloma
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
- Trial name
- CARTITUDE-2 (NCT04133636)
- Testing
- JNJ-68284528, Lenalidomide, Daratumumab
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 208 people
- Sponsor
- Janssen Research & Development, LLC
Myelodysplastic Syndromes, Progressive Disease
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome
This is a phase 1/2 study of the combination of CPI-613 and hydroxychloroquine for the treatment of high risk myelodysplastic syndrome patients who have failed a hypomethylating agent.
- Trial name
- NCT03929211
- Testing
- CPI-613, Hydroxychloroquine
- Where
- 2 sites in United States
- Sponsor
- Wake Forest University Health Sciences
Anemia
Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn
This study aims to determine how maternal Fe status influences placental and neonatal Fe status in pregnant adolescents and to assess the impact of the Fe endowment of birth on functional outcomes as assessed by auditory…
- Trial name
- NCT01019902
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Cornell University
Smoldering Multiple Myeloma
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical…
- Trial name
- NCT05597345
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Rochester
Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and peripheral blood stem cell transplant followed by donor lymphocyte infusion in treating older patients with chronic myeloid leukemia.
- Conditions
- Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease
- Trial name
- NCT00003145
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Ecchymosis; Eyelid, Edema
Topical Tranexamic Acid Application in Rhinoplasty
The aim of this study is to examine the effectiveness of topical Tranexamic acid application in overcoming periorbital ecchymosis and edema after rhinoplasty, which are common and do not have a standard treatment.
- Conditions
- Ecchymosis; Eyelid, Edema, Rhinoplasty
- Trial name
- NCT05326139
- Testing
- Tranexamic acid, Isotonic saline
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Baskent University
Relapsed/Refractory Acute Myeloid Leukemia
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in relapsed/refractory acute myeloid leukemia subjects.
- Trial name
- NCT05518357
- Testing
- LILRB4 STAR-T
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.